1. Scrip
  2. >>New Products

Tetraphase's Broad Spectrum Antibiotic Xerava Priced To Move

 
• By Emily Hayes

Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.

Coming-Soon_1070463245_Alex-Bond_1200.jpg

TetraPhase Pharmaceuticals Inc. is set to launch Xerava – a broad spectrum antibiotic just approved by the US FDA for complicated intra-abdominal infections – at the competitive price of $175-to-$250 a day in a bid to smooth the drug's path on to formularies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.